{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:06Z","timestamp":1793781846893,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["493345156"],"award-info":[{"award-number":["493345156"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA22125"],"award-info":[{"award-number":["CA22125"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114101"],"award-info":[{"award-number":["70114101"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jhep.2025.03.013","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:53:13Z","timestamp":1743043993000},"page":"909-916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-4276","authenticated-orcid":false,"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewon","family":"Hyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9570-3576","authenticated-orcid":false,"given":"Patrick","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4166-6303","authenticated-orcid":false,"given":"Ilhwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Wege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Folprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Sch\u00fctt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-1739","authenticated-orcid":false,"given":"Jaekyung","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8633-2748","authenticated-orcid":false,"given":"Thorsten","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyewon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.03.013_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.013_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"New Eng J Med"},{"key":"10.1016\/j.jhep.2025.03.013_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","author":"Oh","year":"2022","journal-title":"NEJM \u00c9vid"},{"key":"10.1016\/j.jhep.2025.03.013_bib4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.013_bib5","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.03.013_bib6","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/cncr.32463","article-title":"Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes","volume":"125","author":"Lowery","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.03.013_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.03.013_bib8","series-title":"Clinical practice guidelines in Oncology (NCCN guidelines) version 4.2024","year":"2024"},{"key":"10.1016\/j.jhep.2025.03.013_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.03.013_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.013_bib11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.03.013_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.03.013_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","volume":"9","author":"Vogel","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.013_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.013_bib15","doi-asserted-by":"crossref","first-page":"9396","DOI":"10.1002\/cam4.3558","article-title":"nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients","volume":"9","author":"Ueno","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2025.03.013_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cpt.720","article-title":"Population pharmacokinetics of liposomal irinotecan in patients with cancer","volume":"102","author":"Adiwijaya","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.013_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cas.14264","article-title":"Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study","volume":"111","author":"Bang","year":"2020","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.jhep.2025.03.013_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.013_bib19","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.03.013_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2025.03.013_bib21","article-title":"Second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer: a meta-analysis based on individual patient-level data of randomized trials","author":"Hyung","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jhep.2025.03.013_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.03.013_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","author":"Tran","year":"2017","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jhep.2025.03.013_bib24","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.03.013_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.013_bib26","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1200\/JCO.23.01566","article-title":"Nanoliposomal irinotecan with fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced cholangiocarcinoma: a phase II study of the AIO hepatobiliary-YMO cancer groups (NIFE-AIO-YMO HEP-0315)","volume":"42","author":"Ettrich","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.013_bib27","article-title":"BilT03: phase 1b\/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer","author":"Sahai","year":"2024","journal-title":"Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:41:29Z","timestamp":1774860089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0168827825001692"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}